Financial Tearsheet
Company Overview
ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
Recent Financial News
IR Contacts
| LHA Investor Relations |
|
Yvonne Briggs |
Stock Performance
| Today's Open | 1.98 |
| Volume | 952,371 |
| Day Range | 1.98 - 2.22 |
| 52 Week Range | 0.63 - 3.10 |
| Bid/Ask | 2.16 / 2.18 |
| Bid/Ask Size | 400 X 800 |
| Previous Close | 1.98 |
| Market Cap | 90.36 million |
| Shares Outstanding | 41.64 million |
| Dividend/Yield | 0.00 / 0.00% |
| EPS (TTM) | -0.704200 |
| P/E Ratio (TTM) | N/A |
